M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover PharmaphorumRepligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.Read full story pharminent July 22, 2026 (Last updated: July 22, 2026) Pharmaphorum Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028Next: Samsung Biologics: geographic diversification is a sound business decision Related Stories M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026
